<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="4" ids="30225">Positron</z:chebi> emission tomography (PET) is an imaging technique using biological tracers (18-<z:chebi fb="7" ids="24061,30236">fluorine</z:chebi> fluorodeoxyglucose (FDG)), whose uptake into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells is increased </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies carried out in patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> have shown that PET is an accurate method of staging disease and that a high pre-treatment FDG uptake that is abolished by the end of chemotherapy is associated with a good clinical response </plain></SENT>
<SENT sid="2" pm="."><plain>This case report demonstrates that clinical PET scanning can be especially useful in staging patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in whom there is extensive extranodal and marrow involvement, and that PET can follow changes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> viability over a very short time span </plain></SENT>
</text></document>